

Oregon Prescription Drug Affordability Board (PDAB) Regular Meeting Wednesday, February 19, 2025 Minutes approved by the board on March 19, 2025

Web link to the meeting video: https://www.youtube.com/watch?v=-uNlpte8fX8
Web link to the meeting materials: https://dfr.oregon.gov/pdab/Documents/20250219-PDAB-document-package.pdf

Call to order and roll call: Chair Shelley Bailey called the meeting to order at 9:02 a.m. and roll was called.

Board members present: Chair Shelley Bailey, Vice Chair Amy Burns (arrived at 10 a.m.), Dan Hartung (departed at 10:30 a.m.), Lauri Hoagland (arrived at 9:10 a.m.), Dan Kennedy, Chris Laman, John Murray

Absent: None

Declaration of conflict of interest and meetings with entities or individuals related to board activities: John Murray and Robert Judge made statements. View at video minute <u>00:01:20</u>.

Chair Shelley Bailey announced a board executive session on the topic of written legal advice concerning the affordability review process would take place before the start of the agenda item "Board review of data sets and OAR 925-200-0010 criteria for upcoming affordability reviews." The authority for the executive session was ORS 192.660(2)(f). View at video minute <u>00:05:00</u>.

Approval of board minutes: Chair Bailey asked for a motion and second to approve the board minutes as shown on <u>Pages 3-6</u> of the agenda materials. John Murray made a motion to approve the minutes and Dan Kennedy provided a second. View at video minute <u>00:05:37</u>.

MOTION to approve the January 15, 2025, minutes Board Vote:

Yes: Dan Hartung, Lauri Hoagland, Dan Kennedy, Chris Laman, John Murray, Chair Shelley Bailey

No: None

Abstain: Robert Judge

Absent for the vote: Amy Burns

Motion passed 6-0

Executive director's program update: Ralph Magrish, executive director, Oregon Prescription Drug Affordability Board & Drug Price Transparency Program, provided a program update. View the video at minute <u>00:06:48</u>.

Legislative update: Jesse O'Brien, DFR policy manager, provided an update on prescription drug-related bills proposed in the Oregon Legislative session as shown on Pages 6-8 of the agenda materials. View the video at minute O0:11:18.



Public comment: Chair Bailey called on the people who signed up in advance to speak to the board: Lorren Sandt, Caring Ambassadors Program, Tiffany Westrich-Robertson, Patient Inclusion Council/AiArthritis, EACH, Scott D. Bertani, HealthHIV, Dharia McGrew, PhRMA, Nathan Sauser, consumer (was unable to testify due to technical difficulties), Marty Carty, OPCA. The board received 11 written comments, which are posted on the PDAB website. View the speakers at video minute **00:18:14**.

Board discussion and vote on board policies: Cortnee Whitlock, senior policy analyst, continued last month's discussion on amended PDAB Policy and Procedures 1 and Conflict of Interest Policy 3. The board voted to approved policy 1, policy 3, and the conflict of interest form. View the draft board policies on Pages 9-21 of the agenda materials. View the discussion and votes at video minute 00:36:05.

Note: The updated board policies with board approved amendments have been posted to the policies and rulemaking page of the PDAB website:

https://dfr.oregon.gov/pdab/Pages/policies-rulemaking.aspx.

MOTION to approve policy 1 as amended by the board today.

Motion made by Lauri Hoagland with a second by Dan Kennedy.

Board vote:

Yes: Dan Hartung, Lauri Hoagland, Robert Judge, Dan Kennedy, Chris Laman, John Murray, Chair

Shelley Bailey No: None

Absent for the vote: Amy Burns

Motion passed 7-0

MOTION to approve policy 3 as amended.

Motion made by John Murray with a second by Dan Kennedy.

Board vote:

Yes: Dan Hartung, Lauri Hoagland, Robert Judge, Dan Kennedy, Chris Laman, John Murray, Chair

Shelley Bailey No: None

Absent for the vote: Amy Burns

Motion passed 7-0

Board review of annual generic drug report outline: Cortnee Whitlock, senior policy analyst, talked to the board about potential topics for the generic drug report, which will be sent to the Oregon Legislature by June 1. View the topics on Pages 22-24. View the discussion at video minute O0:55:57.



Board discussion about the carrier data call template: The board tabled this item until the March 19, 2025 meeting due to lack of time to get through the agenda items.

Board discussion of affordability review request for information: Cortnee Whitlock, senior policy analyst, talked to the board about the feedback forms designed specifically for each of the following groups: Individuals with scientific or medical training (medical providers, pharmacists, professors); manufacturers; patients, caregivers, advocacy groups, and the general public; pharmacy benefit managers; safety net providers (340B entities). View the topics on Pages 45-55. View the discussion at video minute **01:27:46.**

Executive session, return to open session, roll call: The board adjourned to executive session pursuant to ORS 192.660(2)(f) which allows the board to meet in closed session to consult with counsel concerning legal advice. No decisions were made in executive session. At the end of the executive session, the board returned to open session and roll was called. View the announcement at video minute <u>01:42:04</u>.

Board members present: Chair Shelley Bailey, Vice Chair Amy Burns, Lauri Hoagland, Dan Kennedy, Chris Laman, John Murray

Absent: Dan Hartung

Board review of data sets and OAR 925-200-0010 criteria for upcoming affordability reviews: Cortnee Whitlock led board members in a discussion about the data sets and criteria in OAR 925-200-0010 for the upcoming affordability reviews. Read the slide about the affordability review on Pages 56-58. Here is a link to the spreadsheets on the prescription drug data page. View the discussion at video minute 01:44:59.

Announcements: Chair Bailey announced the next meeting will be March 19, 2025, at 9 a.m. View at video minute <u>02:24:15</u>.

Adjournment: Chair Bailey adjourned the meeting at 12 p.m. with all board members in agreement. View at minute <u>02:24:21</u>.